CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

It's All about the Affinity

Read More
All Posts

In 2012 Roux et al. published in the Journal of Cell Biology a pioneering approach to identify the interactors for the nuclear lamina protein, lamin A, or LaA. Using the novel technique of fusing the E. coli derived biotin ligase BirA protein to LaA and expressing it in cells allowed the cellular neighbors of LaA to be biotinylated. Biotinylated proteins were recovered using strepatividin beads and digested off the beads with trypsin. The resulting peptides were identified using mass spectrometry. Since then, over 7,000 publications have been published using this (and related) proximity labeling technique(s) in cells and tissues derived from higher eukaryotes, xenografts, parasites like toxoplasma gondii and flowering plants.

 

However, the near covalent affinity of streptavidin for biotin (KD~10-14 M) means the biotinylated peptides and site of modification remained firmly bound to the beads. Losing direct identification of the biotinylated peptides can make data analysis more difficult because once biotinylated proteins are modified, they can easily be confused with background, non-specifically bound proteins. For studies like proximity labeling identifying the site of biotinylation provides direct evidence for the site of interaction.

 

So, the extremes to which scientists had to go to uncover what they had successfully enriched for inspired scientists from the Broad Institute and Cell Signaling Technology® (CST®) to create novel methods to significantly improve the recovery of biotinylated peptides. To accomplish this, they employed a combination of antibody-based immunoenrichment techniques and innovative elution conditions to recover biotin-containing peptides.

 

In 2017 Udeshi, N., et al. published in Nature Methods (Nature Methods volume 14pages 1167–1170) a method employing antibodies to selectively enrich for biotinylated peptides from proximity labeling experiments and identify them using mass spectrometry. This new approach from the Carr lab at the Broad Institute led to an improvement of over 30-fold in the identification of biotinylated sites as compared to established methods using streptavidin beads.

 

Meanwhile, leveraging their experience in making PTM-specific enrichment reagents scientists at CST had developed their own anti-biotin rabbit monoclonal antibodies.

CST scientists then partnered with scientists in the Carr laboratory at the Broad Institute to demonstrate further improvements in the method of capturing, releasing and identifying biotinylated peptides by mass spectrometry. In poster presentations at the 2019 Annual Meeting of the American Society for Mass Spectrometry (ASMS) the two groups presented compelling comparative data between various commercially available anti-biotin antibodies that showed CST anti-biotin antibody outperformed all others in the number of biotinylated peptides identified and the overall specificity of the enrichment. In direct comparisons CST anti-biotin antibody recovered well over 4,000 unique biotinylated peptides as compared to 800 peptides for the closest competitor with over 2-fold better specificity, 40% vs 17%. The combination of sensitive and specific antibodies and innovative elution conditions was summarized by the authors as a major contribution to the development of “robust strategies to study post-translational modifications (PTMs) and their biological implications.”

 

Learn more at the liquid chromatography/mass spectrometry proteomics resource center.

Charles Farnsworth, PhD
Charles Farnsworth, PhD
Charles (Chuck) Farnsworth, PhD, was a proteomics application scientist at CST for over 20 years before his retirement in 2024. During his time with CST, he was a lead investigator for the PTMScan product line, as well as a senior proteomics application scientist. Chuck holds his PhD in Biochemistry from Tufts University and was a Leukemia & Lymphoma Society postdoctoral fellow at Harvard Medical School, where he studied developmental biology and signal transduction. In his retirement, you'll find him spending more time doing some of his favorite things including camping with his children and stargazing in the Mad River Valley of Vermont.

Recent Posts

500 Antibodies & Counting: Accelerating Discovery with CST Antibodies Validated for Simple Western Technology

Since 2022, Cell Signaling Technology (CST) and Bio-Techne have been working together to bring best-in-cl...
Chris LaBreck, PhD Oct 23, 2024

Menin-KMT2A Inhibitors: A Promising Approach to Acute Myeloid Leukemia (AML) Treatment

Accounting for about 80% of adult acute leukemias, acute myeloid leukemia (AML) is an aggressive form of ...
Homa Rahnamoun, PhD Oct 16, 2024

CST Turns 25: Celebrating a Quarter Century of Antibodies & Innovations

This year, CST turns 25. As we celebrate this significant milestone, we’re also reflecting on how the res...
Alexandra Foley Sep 24, 2024